Bayer is nearing the end of the road for glyphosate, executives say

Bayer is signaling it has had enough of litigation, leaving the future of a crop protection tool in limbo.

Executives tell the Wall Street Journal they are nearing the end of the road for glyphosate, the main ingredient in RoundUp. CEO Bill Anderson says they are barely breaking even, and litigation costs often put them in the red.

More than 65,000 cases are pending against Bayer right now, and the company has around $16 billion set aside for settlements.

Anderson stands by glyphosate, saying it has been proven safe to use, even by the FDA. Bayer produces roughly 40 percent of the supply used by U.S. farmers.

LATEST STORIES BY THIS AUTHOR:

American Farm Bureau Federation (AFBF) economist Danny Munch joined us on Thursday’s Market Day Report to break down the scope of the U.S. Christmas Tree industry and what growers are up against.
Canadian tariffs would raise costs for potash, ammonia, and UAN, increasing spring fertilizer risk.
Lewis Williamson with HTS Commodities breaks down the outlook on grain storage and domestic supply chain strength as producers weigh planting decisions with forthcoming federal aid.
Experts say flooding the zone with more money could have unintented consequences without opening new markets for planted crops and inputs under significant pressure.
Julie Callahan was nominated earlier this summer by President Donald Trump, and U.S. Trade Representative Jamieson Greer told lawmakers she is ready to hit the ground running.